The company is a fixed-fee volume engine that beat on reliability, is forward-sold through year-end, has a funded ramp to 60–63 MTPA nearly complete, and is retiring roughly 3% of its shares a year.
Read Article ›The market's error here is not the 50% de-rating — three guide-downs earned it — but the assumption that the cutting continues.
Read Article ›At 15.5 times forward earnings and a 6.6% cash yield on enterprise value, the market is not pricing a debate, it is pricing an answer – and the answer it has chosen is contradicted by every disclosure FactSet has made since the shares halved.
Read Article ›The bull case needs nothing new — only that a brand posting 17% growth in its own channels, with inventory down 5% and a raised earnings guide, is not the brand that gets caught in someone else's clearance event.
Read Article ›What tips the balance is that the approval was not the whole catalyst — it was the start of a data stream that gets richer, not thinner, from here.
Read Article ›Guidance went up, not down; the contract book lengthened; a landmark acquisition closed and its integration proceeded on plan.
Read Article ›The reason the multiple is compressed is not that anyone doubts the ad engine; it is that Meta, alone among the hyperscalers, has no third-party cloud line absorbing the spend.
Read Article ›The harder, less-discussed truth about BridgeBio is that the equity sitting on top of this franchise is a thin residual behind a capital structure that private-credit and private-equity sponsors engineered to harvest the ramp first.
Read Article ›The market broke this stock on a narrative about 2028 and has not fully repaired it against an operating record that keeps improving.
Read Article ›At ~19x forward earnings on a franchise whose fee rate has inflected up after a decade of compression, with capital return stepping up and the two genuine risks slow-burning and priced into the downside case, BlackRock is worth owning through the volatility — not because it is...
Read Article ›The catalyst the market is under-weighting is the second derivative on organic billings: a steepening curve off a de-risked trough, with a bankrupt-tenant claim thrown in for free. The catalyst that broke this stock — the fiber write-downs, the dividend cut, the DISH default, ...
Read Article ›The discount as struck double-counts Argentina — once in the multiple and again in the reflex to distrust cash flows that are demonstrably Brent-linked and demonstrably deleveraging the balance sheet. The tape has earned back at least one of those two discounts.
Read Article ›Quanta is priced as a high-quality compounder rather than a bargain, and the near-term estimate momentum still points up as the raised guide and the un-booked corridor stacking feed the next several prints.
Read Article ›The risk-reward here is skewed favorably for a specific and unusual reason: the earnings math is more knowable than that of almost any agency, and the market is charging almost nothing for it. The category is structurally challenged and the franchise is thin — those are real, ...
Read Article ›Dave is a genuinely compounding franchise with a data moat, temporarily mispriced because the market read a high-return reinvestment decision as margin decay, carrying a real and unreserved regulatory tail that justifies a discounted multiple but not the one the market assigne...
Read Article ›The signed backlog says the consensus deceleration curve is too steep, and while that gap persists the stock can grind higher on upward revisions rather than on further multiple expansion. That is the constructive case, and it is a real one: bookings running ahead of revenue, ...
Read Article ›For years the bear objection to WESCO's data-center growth was structural: hyperscale projects are enormous but competitively bid, and volume that dilutes margin is worth less than the revenue line suggests.
Read Article ›The hinge of the whole situation is a single line in the second-quarter results. Strip it out and clean 2026 earnings power sits closer to $15 a share — and 2027 then benefits a second time, because the refinancing itself lowers the ongoing interest bill.
Read Article ›The market is treating a normalizing-from-peak renewable-diesel earner as a fluke and pricing the whole enterprise as a commodity rendering play, when the balance sheet is de-risking fast, the buyback retires a tenth of the float, and the collagen core compounds on its own clock.
Read Article ›The thesis lives in the hotels; the entertainment arm is a call option the market keeps trying to price and, I will argue, is getting wrong in a way that is more nuisance than opportunity.
Read Article ›The de-rating question the setup poses answers itself when you look closely: the stock is not down on a broken thesis but off its high in a broad healthcare drawdown, and the June quarter was a clean beat with a raise. So the honest verdict is not that McKesson is mispriced — ...
Read Article ›